VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nat Commun. 2021 05 10; 12(1):2606.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung
CD4-Positive T-Lymphocytes
Cell Line, Tumor
Drug Resistance, Neoplasm
Drug Synergism
Female
Humans
Immunohistochemistry
Lung Neoplasms
Male
MAP Kinase Signaling System
Mice
Mice, Knockout
Mitogen-Activated Protein Kinase Kinases
Neoplasm Invasiveness
Neoplasm Metastasis
Protein Kinase Inhibitors
Proto-Oncogene Proteins p21(ras)
Th17 Cells
Tumor Suppressor Protein p53
authors with profiles
LAUREN AVERETT BYERS
DON LYNN GIBBONS